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chronic inﬂammation. The study aimed at controlling inﬂamma-
tion using sulfasalazine 500 mg, once a day treatment in compar-
ison to placebo in MetS patients.
Methods: A double blind, randomized, placebo controlled study
was carried at Sadbhavna Medical and Heart Institute, Patiala. 50
eligible subjects (Male/Female = 45/5, n = 25/group), fulﬁlling the
National Cholesterol education Program-Adult Treatment Panel
(NCEP-ATP III) diagnostic criteria of MetS, were randomly assigned
to once daily drug or placebo tablets for 20 weeks. Blood pressure,
hsCRP, TNF-a, lipid proﬁle, fasting plasma glucose and insulin
levels, homeostatic model assessment-insulin resistance
(HOMA-IR), endothelial-dependent ﬂow-mediated dilation (FMD)
of brachial artery, right common carotid intima-media thickness
(IMT) and artery stiffness indices [(Young elastic modulus (YEM),
stiffness index (SI) and carotid arterial compliance (CAC)] by Dop-
pler Ultrasound were assessed at baseline and after 20 weeks
treatment. Tolerability was measured using hematological and
biochemical analysis. Statistical signiﬁcance was accepted at
p ≤ .05.
Results: FMD improved as 25.66  6.47% versus 12.41  3.22%,
p < 0.01; and HOMA-IR decreased as 7.05  3.48 versus 11.32
 6.08, p < 0.01, from baseline in drug group as compared to pla-
cebo group, whereas endothelium-independent vasodilatation
( p = 0.23) and baseline brachial artery diameter ( p = 0.95) remained
unchanged in both the groups. Serum triglyceride ( p = 0.04), hsCRP
( p < 0.01) and TNF-a ( p < 0.01) levels were considerably altered,
but there was no effect on carotid IMT, YEM, CAC and SI (all
p ≥ 0.05). Safety variables were signiﬁcantly altered, but were still
found with-in the normal limits.
Conclusion: Thus, sulfasalazine may prevent CVD risk by reducing
insulin resistance and endothelial dysfunction via halting inﬂam-
matory process.
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This paper brings forth a rare case of Marfan Syndrome with Type-
1 diabetes and pulmonary tuberculosis.
A 17-year-old male presented to our hospital in an emaciated
condition with complaints of polyuria, cough and fever. Based
on patients history, clinical and standard laboratory assessment
he was diagnosed with Type-1 diabetes. His chest radiograph and
sputum examination conﬁrmed the diagnosis of pulmonary tuber-
culosis. In countries like India, diabetes remains one of the most
important risk factors predisposing towards tuberculosis. The
development of tuberculosis occurred 10 times more frequently
in type-1 diabetics. The diagnosis of MFS was made according to
the ‘‘Revised Ghent criteria’’ taking into consideration the features
of eyes, cardiovascular system, skeleton, skin, and respiratory
system in the present case.
Marfan Syndrome, a rare autosomal dominant disorder was ﬁrst
reported way back in 1896 by Antonin Marfan. Abnormal signaling
of Transforming Growth Factor-b (TGF-b) has been implicated in
pathogenesis of MFS. TGF-b was found to have several immuno-
logical effects, but its role in the pathogenesis of type-1 and type-2
diabetes is still not well understood.
The association of MFS with type-1 diabetes was rarely reported in
the past. After a thorough review of literature, only two cases of
MFS with type-1 diabetes have been reported around the world so
far. Although this co-occurrence can be coincidental, a common
immunological pathway pertaining to TGF-bmay exist. This paper,
henceforth, lays emphasis on intense research on these speciﬁc
developments.
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Aim: To assess the correlation of LVDD with CIMT (carotid intima
media thickness) and baPWV – the subclinical atherosclerotic risk
markers.
Methods: 565 with diabetesmellitus, aged between 35 and 75 years
were evaluated for left LVDD using Doppler Echo. LVDD was
determined by using conventional 2-Decho and Doppler techni-
ques and LVDDwas graded as grade I, II, III, and IV, as per standard
norms. Parameters such as CIMT, baPWV, ABI, SBP, DBP, Lipid
Proﬁle, HbA1c, duration of diabetes, andWHR were included. LVEF
was considered as a measure of systolic dysfunction.
Results: LVDD was observed in 84.6% of patients. Predominant
patternwas abnormal relaxation (58%)with highest in age group of
35–73 years. Out of 565 patients studied, total 478 (84.6%) had
LVDD, 347 patients (69.4%) had (Grade 1 DD), 104 patients
(20.8%) had (Grade 2), 27 patients (5.4%) had (Grade 3). 87 out
(15.4%) had no evidence of diastolic dysfunction. LVDD was found
to have signiﬁcant correlation with SBP ( p = 0.015), ABI ( p = 0.034),
LDL ( p = 0.06), HDL ( p = 0.07) and TG's ( p = 0.18). Correlation of
LVDD with PWV and CIMT is found to be mild signiﬁcant.
Conclusion: LVDD had mild correlation with CIMT and PWV in
this group of population. Since both CIMT and PWV are future
cardiovascular risk markers, such correlation warrants screening
of diabetic population for these atherosclerotic risk markers
for prevention of future cardiovascular risk. However, larger
study is needed to observe more correlation between these
parameters.
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Background and aims: Microalbuminuria has been identiﬁed as a
predictor of renal failure and an independent risk factor for car-
diovascular disease in patients with diabetes mellitus as well as in
general population. This study was aimed to determine the corre-
lation of microalbuminuria with Obesity and Cardiovascular risk
markers.
Methods and materials: 2044 type-II diabetes patients were
enrolled in the study. Microalbuminuria in all the subjects was
estimated and the albumin to creatinine ratio (A:C) determined.
Obesity parameters (BMI, WHR), HbA1c, baPWV, Blood Pressure,
ABI, LDL, HDL, TGs of all the subjects were also measured. baPWV
was measured with VP-2000/1000-Colin Corporation, (hyayashi
komaki Japan). Microalbuminuria was measured Clinitek status
Analyzer (Bayer Health Care).
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